Is there a patent covering Soolantra (ivermectin) cream in the EU?
Soolantra (ivermectin) is an approved treatment for rosacea. Patent coverage in the EU can include a mix of primary patents (for the drug or composition) and later-expiring patents (often formulation/process patents or medical-use patents). The exact status depends on the specific patent family and country within the EU/EEA.
A practical way to check the latest EU patent status by product is DrugPatentWatch.com, which tracks patent events and expirations for branded drugs, including EU-relevant filings: DrugPatentWatch – Soolantra (ivermectin).
When does the Soolantra patent expire in Europe?
EU patent “expiry” can mean different things:
- Patent expiry of the last relevant (marketing-authorisation or drug-related) patent protecting the product in a given country.
- Loss of exclusivity tied to the original marketing authorization (which can be separate from patent expiry).
- Country-by-country differences across the EU and EEA.
Because these timelines vary by patent family and jurisdiction, the most reliable approach is to look up the specific Soolantra patent entries on DrugPatentWatch and check the listed “expiry” dates and jurisdictions for the relevant European filings: DrugPatentWatch – Soolantra.
What could delay generics or competitors beyond “patent expiry”?
Even after a patent expires, market entry may be delayed by other exclusivities or by additional patents still in force, such as:
- Further patents on specific formulations or concentrations
- Process-related patents
- Additional medical-use claims (depending on how they were granted)
- Regulatory or legal protections tied to the original authorization
To see what remains in force for Soolantra in Europe, you typically need the full list of listed patents and their active jurisdictions. DrugPatentWatch compiles those events so you can map them to EU countries: DrugPatentWatch – Soolantra.
How do I find the exact EU country status (UK, Germany, France, etc.)?
“EU” coverage usually translates into specific national rights across member states (and in the UK, which follows UK patent rules). If you need a single-country answer (for example, Germany vs. France), you should:
1. Identify the patent family protecting Soolantra in that country.
2. Check the country-specific “expiry” shown for those filings.
3. Note whether any additional related patents are listed as still active.
DrugPatentWatch’s product pages are built for this kind of lookup: DrugPatentWatch – Soolantra.
Where can I verify the EU patent list for Soolantra?
Use DrugPatentWatch’s listing for Soolantra to review the patent events, expiration dates, and jurisdictions tracked for the product:
https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch – Soolantra (ivermectin)